GlassScriptPhysician profile
John Mark Litchfield
NPI 1730329533
$23,417.47
in general payments reported to CMS, 2019-2025
40 companies · $1,741 in 2025
The $1,741 reported for 2025 was more than what 76% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $418 · 2021: $1,110 · 2022: $1,396 · 2023: $1,302 · 2024: $2,154 · 2025: $1,741.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,175 · Education: $22.58.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,174.59 |
| Education | $22.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15,223.77 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Abbvie INC. | $2,605.02 | 2019-2025 | |
| Janssen Biotech, INC. | $871.41 | 2019-2025 | Tremfya, Stelara, Remicade |
| Gilead Sciences, INC. | $430.48 | 2020-2025 | |
| Pfizer INC. | $381.50 | 2019-2025 | |
| Qol Medical, LLC | $357.20 | 2019-2024 | Sucraid, Sucraid |
| Takeda Pharmaceuticals U.S.A., INC. | $346.78 | 2019-2025 | Entyvio |
| Genzyme Corporation | $342.40 | 2023-2025 | |
| Ardelyx, INC. | $299.94 | 2022-2025 | Ibsrela |
| Evoke Pharma, INC. | $263.55 | 2024-2025 | |
| Celgene Corporation | $257.47 | 2021-2024 | Zeposia |
| Intercept Pharmaceuticals, INC. | $195.16 | 2019-2025 | Ocaliva |
| Ironwood Pharmaceuticals, INC | $155.11 | 2020-2024 | Linzess |
| Phathom Pharmaceuticals, INC. | $150.56 | 2024-2025 | Voquezna |
| Madrigal Pharmaceuticals | $143.86 | 2024-2025 | Rezdiffra, Resmetirom |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $142.11 | 2024-2025 | Renflexis, Hadlima |
| Alnylam Pharmaceuticals INC. | $131.85 | 2021-2025 | Givlaari |
| Regeneron Healthcare Solutions, INC. | $117.25 | 2022-2025 | Dupixent |
| Amgen INC. | $113.37 | 2021-2023 | Avsola, Amjevita |
| Lilly USA, LLC | $111.37 | 2023-2025 | Omvoh |
| Celltrion USA INC. | $90.86 | 2024-2025 | Vegzelma, Zymfentra |
| Ferring Pharmaceuticals INC. | $77.74 | 2023-2024 | Rebyota |
| Daiichi Sankyo INC. | $77.47 | 2019-2023 | Injectafer |
| Medtronic USA, INC. | $67.71 | 2019 | |
| Nestle Healthcare Nutrition INC. | $65.56 | 2021-2023 | |
| Shire North American Group INC | $60.26 | 2019 | |
| Braintree Laboratories, INC. | $55.28 | 2019-2021 | |
| Axonics, INC. | $47.63 | 2022-2024 | Axonics |
| Vivus LLC | $44.07 | 2021-2025 | Pancreaze |
| Shionogi INC | $32.40 | 2019 | |
| Boston Scientific Corporation | $23.23 | 2021-2025 | Axonics |
| Aimmune Therapeutics, INC. | $19.50 | 2025 | Zenpep |
| Redhill Biopharma INC. | $17.89 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.15 | 2023 | Cyltezo |
| Merck Sharp & Dohme LLC | $14.51 | 2020 | |
| Alfasigma USA, INC. | $13.73 | 2021 | |
| Allergan, INC. | $13.70 | 2020 | |
| Medtronic, INC. | $13.59 | 2022 | |
| Azurity Pharmaceuticals, INC. | $13.57 | 2025 | Sutab |
| Lucid Diagnostics INC. | $13.46 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Litchfield listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.